Moleculin Biotech, Inc.
MBRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001659617
In the last 90 days, Moleculin Biotech, Inc. insiders filed 3 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $518.5K in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Moleculin Biotech, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 24 | 19 | −5 |
| SharesConverted for a 1-for-15 split | 345.6K | 258.5K | −87.1K (−25.2%) |
| Value | $4.44M | $1.53M | −$2.91M (−65.6%) |
New holders (3)
Institutions that held Moleculin Biotech, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Newbridge Financial Services Group, Inc. | 685 | $4.05K | 0.00% |
| FWL Investment Management, LLC | 278 | $1.64K | 0.00% |
| NBC Securities, Inc. | 14 | – | – |
Sold out (8)
Institutions that held Moleculin Biotech, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Renaissance Technologies LLC | 129,600 | $111.0K |
| State Street Corp | 71,397 | $61.3K |
| Citadel Advisors LLC | 64,652 | $55.5K |
| Northern Trust Corp | 53,596 | $46.0K |
| Schmidt P J Investment Management Inc | 29,000 | $14.1K |
| Jmac Enterprises LLC | 13,132 | $11.3K |
| Sigma Planning Corp | 12,000 | $10.3K |
| Hazlett, Burt & Watson, Inc. | 67 | $0 |